Drugs / PMG1015
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05895565 | May 2023 → Feb 2025 | idiopathic pulmonary fibrosis | Pulmongene Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05022771 | Oct 2021 → Aug 2022 | idiopathic pulmonary fibrosis | Pulmongene Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PMG1015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05895565 ↗ |
| Modality | Monoclonal antibody | “PMG1015 is a monoclonal antibody” NCT05022771 ↗ |